Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH; IAP in Italian) is a disease of the pulmonary microcirculation in which increased resistance to blood flow causes progressive right ventricular overload. It corresponds to group 1 of the clinical classification of pulmonary hypertension: it encompasses conditions with different origins that share a predominantly arterial vascular disease and a precapillary hemodynamic profile. The term therefore does not refer to every increase in pulmonary artery pressure and is not synonymous with pulmonary hypertension caused by left heart disease, respiratory disorders or chronic thromboembolic obstruction.

Its clinical importance stems from the interaction between vascular injury and the ability of the right heart to adapt. An initially modest reduction in circulatory reserve may only become apparent during exertion; as vascular bed obstruction becomes extensive, cardiac output fails to increase adequately and, in advanced stages, falls even at rest. Early diagnosis, correct etiologic classification and reassessment of treatment response can alter the disease course but require specialist management that considers the pulmonary vessels, right ventricle and associated conditions together.

Definition and boundaries of the disease

The definition requires invasive measurement by right heart catheterization. The precapillary profile is characterized by a mean pulmonary arterial pressure above 20 mmHg at rest, pulmonary arterial wedge pressure no higher than 15 mmHg and pulmonary vascular resistance above 2 Wood units. These values describe a circulatory abnormality but do not independently establish its cause: advanced lung disease or chronic thromboembolic disease may produce the same profile. Establishing a diagnosis of PAH requires showing that the condition belongs to group 1 following an adequate differential assessment.

Pulmonary vascular resistance represents the ratio of the pressure gradient across the pulmonary circulation to cardiac output. Considering resistance helps avoid confusing pressure elevation due to increased flow with true resistance-related vascular disease. Wedge pressure, in turn, is used to estimate the contribution of left heart filling pressures, but must be correctly acquired and interpreted: obesity, respiratory pressure fluctuations, volume status and concomitant heart disease may make an isolated measurement insufficient.

Current hemodynamic thresholds identify milder abnormalities than those used in many historical therapeutic trials. This does not mean that every person with values only slightly above the threshold should automatically receive the same medications used in established PAH. In early disease, the probability of progressive pulmonary vascular disease, predisposing factors, symptoms and longitudinal monitoring matter. Distinguishing a diagnostic definition from a treatment indication prevents a classification criterion from becoming a prescription without adequate clinical justification.

Origins and principal clinical forms

When no associated condition, causal exposure or identifiable genetic origin is found, the condition is termed idiopathic pulmonary arterial hypertension. This is a diagnosis of exclusion that may be reconsidered if subsequent testing reveals a previously unrecognized cause. The heritable form includes familial cases and disease associated with pathogenic genetic variants, even when no other family member is clinically affected. Incomplete penetrance explains why a predisposition may pass through several generations without evident manifestations.

Another category is medication- and toxin-associated PAH, in which exposure history can change both classification and treatment. A causal relationship is well documented for some substances, whereas for others it remains possible and calls for caution in interpretation. Discontinuing the causative agent may improve the condition without guaranteeing complete regression of established vascular remodeling.

Associated forms primarily include connective tissue diseases, congenital heart diseases with shunts, portal hypertension, HIV infection and schistosomiasis. In connective tissue diseases, particularly systemic sclerosis, pulmonary vascular disease may coexist with pulmonary fibrosis or left heart dysfunction: identifying the predominant mechanism is decisive. Similarly, the high blood flow associated with cirrhosis or a shunt is not sufficient by itself to define PAH, because pathological elevation of vascular resistance must be documented.

Group 1 also includes venous and capillary involvement, including pulmonary veno-occlusive disease. Although this phenotype may present with hemodynamics that appear indistinguishable from arterial disease, it is characterized by hypoxemia, reduced alveolar-capillary diffusing capacity and characteristic radiological findings. Recognizing it is essential because vasodilatation can cause pulmonary edema and therapeutic management requires special precautions.

Pulmonary vascular pathogenesis and right ventricular adaptation

The fundamental lesion mainly affects small pulmonary arteries and arterioles. The endothelium loses some of its vasodilatory, antithrombotic and cell growth-regulating properties; smooth muscle cells and fibroblasts contribute to wall thickening and extracellular matrix accumulation. Luminal narrowing therefore does not result solely from reversible vasoconstriction: it includes structural remodeling that may persist even after vascular tone is reduced pharmacologically.

Changes in the endothelin, nitric oxide and prostacyclin pathways link pathophysiology to traditional pulmonary vascular treatments. Signaling through the TGF-β superfamily, including the BMPR2 pathway, contributes to regulation of cell proliferation, survival and repair. In some patients the abnormality is genetically determined; in others, inflammation, oxidative stress, metabolic disturbances and environmental factors play a role. Plexiform lesions are a possible feature of advanced disease, not a finding that must be demonstrated by biopsy to establish the diagnosis.

Increased resistance and reduced arterial distensibility raise both the resistive and pulsatile load on the right ventricle. Initially, hypertrophy and increased contractility maintain adequate cardiac output. When compensation becomes insufficient, dilatation, tricuspid regurgitation and elevated venous pressures develop. Septal displacement and competition for pericardial space also reduce left ventricular filling, contributing to low systemic cardiac output.

This relationship explains why two people with similar pulmonary pressures may have very different disease severity. Prognosis depends mainly on the right heart's ability to sustain the load and its response to treatment. Even a decrease in pulmonary pressure, if accompanied by falling cardiac output, may reflect deterioration. Pressure measurements are meaningful only alongside ventricular function, systemic perfusion and congestion.

Clinical manifestations and diagnostic suspicion

The most common symptom is exertional dyspnea, often accompanied by fatigability and reduced tolerance of usual activities. Initially, a person may compensate by slowing down or avoiding hills without recognizing an actual limitation. Nonspecific symptoms favor diagnostic delays, especially when anemia, excess weight, anxiety or mild respiratory disease seem to provide a sufficient explanation. Progression, disproportionate symptoms relative to pulmonary findings and the presence of predisposing factors should increase suspicion.

Presyncope and syncope, particularly during exertion, indicate an inability to maintain adequate cerebral perfusion and require timely assessment. Chest pain and palpitations may arise from cardiac overload or arrhythmias; dependent edema, abdominal distension and anorexia suggest systemic venous congestion. Hemoptysis, although less common, requires specific evaluation and must not automatically be attributed to elevated pulmonary pressure alone.

The physical examination may reveal little in early disease. Later findings may include an accentuated pulmonary component of the second heart sound, a right parasternal heave and a murmur of tricuspid regurgitation. Jugular venous distension, hepatomegaly, ascites and edema reflect the hemodynamic consequences of right heart decompensation. Signs of systemic sclerosis, liver disease, congenital heart disease or respiratory illness instead provide clues to the cause. Clinical assessment must therefore seek both circulatory severity and etiologic clues.

From initial investigations to hemodynamic confirmation

Echocardiography estimates the probability of pulmonary hypertension based on tricuspid regurgitation velocity and other signs of right heart overload, but cannot independently confirm PAH. It should describe right heart chamber size and function, the interventricular septum, inferior vena cava, valves and left heart characteristics. An apparently normal pressure estimate does not exclude disease when the Doppler signal is inadequate or clinical suspicion remains high.

Pulmonary function tests, including DLCO, arterial blood gas analysis and chest CT allow assessment of lung parenchyma and gas exchange. Ventilation/perfusion scintigraphy is central to excluding chronic thromboembolic disease, even without a documented history of pulmonary embolism. Blood tests investigate anemia, renal or hepatic dysfunction, thyroid abnormalities and associated conditions; autoimmune testing, HIV serology and liver investigations are integrated into the etiologic workup. The absence of an evident cause in the history does not make these investigations unnecessary.

Right heart catheterization measures pressures, cardiac output, oxygen saturations and vascular resistance, allowing precapillary vascular disease to be distinguished from a postcapillary component. In selected cases, additional wedge pressure checks, shunt assessments or provocative maneuvers may be required to clarify possible occult left heart disease. The vasoreactivity test serves a different purpose: in idiopathic, heritable and medication-associated forms, it identifies the small proportion of patients who may be candidates for high-dose calcium channel blockers. It is not a universal test of PAH reversibility.

The final diagnosis results from integrating all findings. Invasive measurements consistent with PAH, a CT scan without significant respiratory disease and perfusion scintigraphy without typical defects are not interchangeable observations: each excludes a different mechanism. Genetic counseling, when indicated, adds information for the patient and family without replacing clinical characterization.

Staging, risk and treatment targets

After diagnosis, it is necessary to determine how much the disease affects everyday life and the risk of deterioration. WHO functional class, six-minute walk distance and BNP or NT-proBNP levels provide complementary information. Right ventricular imaging, right atrial pressure, cardiac index and mixed venous oxygen saturation complete the assessment, particularly when symptoms and test results are discordant.

Prognostic models distinguish risk categories and help structure decisions but do not replace clinical judgment. During follow-up, the four-stratum approach separates intermediate-low from intermediate-high risk. A patient who has improved since diagnosis may still have clinically important residual risk: the objective is not merely to achieve perceived benefit but, where possible, to attain and maintain a low-risk profile.

Reassessment also includes adherence, tolerability, physical activity, oxygenation and coexisting conditions. Age, kidney disease, anemia and musculoskeletal problems may affect biomarkers and walking distance; they must be recognized without automatically attributing every abnormality to PAH. Recent deterioration, syncope, hospitalization for heart failure or rapidly developing congestion carry clinical weight that an average score might obscure. The strategy must therefore remain dynamic.

Treatment and continuity of care

Treatment combines supportive measures with agents targeting pulmonary vascular disease. Diuretics control congestion, oxygen is prescribed when indicated by hypoxemia, and supervised exercise may improve functional capacity in clinically stable patients. Education, appropriate vaccinations, psychological support and management of iron deficiency are part of care. Pregnancy carries a high risk and requires specialist counseling; anticoagulation is not automatically indicated for every form.

In patients with a classic phenotype and low or intermediate risk, an initial combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor is often used. High-risk disease requires a more intensive strategy, generally including a parenteral prostacyclin. Riociguat, prostacyclin receptor agonists and prostacyclin analogues are used in selected pathways; riociguat must not be combined with phosphodiesterase type 5 inhibitors. In patients with significant cardiopulmonary comorbidities, initial treatment selection and escalation require greater individualization.

Sotatercept introduces a different target by modulating TGF-β superfamily signaling involved in vascular remodeling. The STELLAR, ZENITH and HYPERION trials have expanded evidence for its use in addition to background therapy in defined adult PAH populations. Interpretation must respect the populations and objectives of these studies: demonstrated benefit does not justify extending treatment to all forms of pulmonary hypertension. Hemoglobin, platelets and bleeding risk require monitoring.

An inadequate response calls for timely escalation and, in appropriate patients, assessment for lung transplantation. Calcium channel blockers represent a separate pathway reserved for selected patients with a positive vasoreactivity test and sustained clinical and hemodynamic response. When an associated condition is present, its treatment proceeds alongside management of pulmonary vascular disease: discontinuing a causative substance, controlling autoimmune disease or determining whether a shunt can be corrected requires specific expertise and cannot be replaced with a uniform prescription.

Prognosis and complications

Prognosis has improved with earlier diagnosis and combined treatment strategies, but remains heterogeneous. Etiology, phenotype, right ventricular function and residual risk during treatment are more informative than an isolated pressure measurement. Survival estimates from registries covering different eras do not automatically predict an individual patient's outcome and must be interpreted in light of available therapies and the characteristics of the population studied.

The central complication is right ventricular failure, which may be accompanied by kidney injury, hepatic congestion, hypotension and low cardiac output. Atrial arrhythmias are often poorly tolerated because they impair filling and the contribution of atrial contraction. Infections, anemia, surgery and treatment interruptions may precipitate decompensation; abrupt discontinuation of a parenteral prostacyclin is a particularly dangerous emergency.

Hemoptysis, marked pulmonary artery dilatation and compression of adjacent structures are additional, less common but clinically significant complications. Management requires distinguishing spontaneous disease deterioration from treatment adverse effects and intercurrent illnesses. Continuous follow-up at an expert center allows these changes to be recognized and treatment adapted before loss of cardiac reserve becomes difficult to reverse.

References
  1. Humbert M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618–3731.
  2. Kovacs G et al. Definition, classification and diagnosis of pulmonary hypertension. European Respiratory Journal. 2024;64(4):2401324.
  3. Mocumbi A et al. Pulmonary hypertension. Nature Reviews Disease Primers. 2024;10(1):1.
  4. Guignabert C et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. European Respiratory Journal. 2024;64(4):2401095.
  5. Hemnes AR et al. Pathophysiology of the right ventricle and its pulmonary vascular interaction. European Respiratory Journal. 2024;64(4):2401321.
  6. Chin KM et al. Treatment algorithm for pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4):2401325.
  7. Eichstaedt CA et al. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. European Respiratory Journal. 2023;61(2):2201471.
  8. Hoeper MM et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal. 2022;60(1):2102311.
  9. Galiè N et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. The New England Journal of Medicine. 2015;373(9):834–844.
  10. Hoeper MM et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. The New England Journal of Medicine. 2023;388(16):1478–1490.
  11. Humbert M et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. The New England Journal of Medicine. 2025;392(20):1987–2000.
  12. McLaughlin VV et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. The New England Journal of Medicine. 2025;393(16):1599–1611.
  13. Hoeper MM et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801906.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.